

## Appendix A: Stakeholder consultation comments table

### 2021 surveillance of Headaches in over 12s: diagnosis and management (2012)

Consultation dates: 26<sup>th</sup> August to 9<sup>th</sup> September 2021

1. Do you agree with the proposals to change recommendation 1.3.15 about metoclopramide and prochlorperazine for the treatment of acute headache from an 'offer' to a 'consider' recommendation and to add wording to the recommendation reminding practitioners to check the specific product characteristics (SPCs) of these drugs for safety warnings?

Stakeholder	Overall response	Comments	NICE response
Royal College of Paediatrics and Child Health	Yes	<p>The reviewer noted that metoclopramide or prochlorperazine is rarely used in their practice. This is mainly due to the side effects.</p> <p>Using "consider" rather than "offer" in the management of migraine is important as it helps better reflect the benefits and harms of these drugs.</p> <p>Has the use of Ondansetron been considered, if not why not?</p>	<p>Thank you for your comments.</p> <p>Like metoclopramide and prochlorperazine ondansetron is not licensed for treatment of headache. However, we found evidence for the effectiveness of metoclopramide and prochlorperazine for management of headache during guideline development and the guideline development group were able to make recommendations based on this evidence (see <a href="#">full guideline</a>). We have not identified evidence for the effectiveness of ondansetron in this population and therefore cannot make recommendations.</p>

*Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees*

Royal College of Nursing	Yes	We support the amendment of the proposal wording to: 'consider' a non- oral preparation of metoclopramide or prochlorperazine. The rationale in the amendment is perfectly clear. We feel metoclopramide is used regularly in practice as it is very effective and generally better tolerated.	Thank you for your comments.
--------------------------	-----	--	------------------------------

© NICE 2019. All rights reserved. Subject to [Notice of rights](#).

*Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees*